Biotechnology

Natural Alternatives International posts a 23% sales surge but a wider net loss, betting on new financing and product innovation to fix profitability woes.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

With backing from Bain Capital and Armistice, the life sciences firm's latest offering aims to fund its push to automate pharmaceutical quality control.

A PIF company becomes the first Saudi entity to join a top global genomics forum, a strategic move under Vision 2030 to shape the future of healthcare.

A $200,000 donation, part of a $1M commitment, funds vital cancer research and celebrates one young girl's triumphant journey to recovery.

As Avid Bioservices scales up, new Chief People Officer Maria Ebro Andreasen is tasked with building a talent pipeline in a fiercely competitive market.

With a new CSO known for pushing rare disease drugs to market, Arbor Biotechnologies signals a strategic shift from platform discovery to clinical execution.

Quince Therapeutics' drug LAM-001 posts strong Phase 2a data, showing meaningful functional gains for patients with severe pulmonary hypertension.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.

A strategic investment from Olayan Financing Company positions MS Pharma to dominate the MENA biologics market, fueling Saudi Arabia's Vision 2030 goals.

Biotheryx's novel protein degrader, BTX-9341, shows impressive safety and efficacy in patients who have progressed on standard therapies.

A new partnership with AI firm Basepath Health will help Children's Mercy treat five times more children with complex and rare genetic diseases.

New FolinicActive™ offers a multi-pathway folate for the 15-25% of adults who report adverse effects from standard L-methylfolate supplements.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

With 12% weight loss in a pivotal trial, Vincentage Pharma's VCT220 pill is set to challenge injectables and reshape China's obesity drug market.

The life sciences news hub earned prestigious Neal and Azbee National Gold awards, highlighting the growing influence of expert-driven B2B journalism.

The biotech firm raises cash via a complex warrant deal, diluting shares to fund its promising but challenging RNAi therapy for deadly KRAS-driven cancers.

New data reveals TARA-002 has a 55% complete response rate at one year for NMIBC, offering a promising, safer alternative to standard care.

A new oral drug for depression shows rapid, robust effects in a key trial, offering hope for millions by targeting a different brain pathway.